Biologics / Biotechnology

#Biologics / Biotechnology #Cell therapy #Clinical trials #Drug development #Drug discovery #Gene therapy #Imaging #Immunology #Microbiology #RNA #Stem cells #System biology

Taconic Biosciences to distribute critical COVID-19 mouse model

Taconic Biosciences has announced an exclusive agreement with the University of Texas Medical Branch at Galveston (UTMB) to distribute humanised ACE2 mice for coronavirus research. The SARS-CoV-2 virus, which causes COVID-19, uses the ACE2 receptor to enter cells, causing infection. Due to differences between the mouse and human… Read More

#Covid-19 #News

#Biologics / Biotechnology #Cell therapy #Cellular assays #Clinical trials #Drug development #Drug discovery #Gene therapy #Imaging #Immunology #Stem cells

Avacta collaboration offers update on Affimer therapy for COVID-19

Avacta Group, in collaboration with the Centre for Virus Research at the University of Glasgow, has shown that Affimer reagents which bind to the SARS-COV-2 virus spike protein, prevent infection of human cells by a SARS-COV-2 model virus and therefore provide a potential therapy for COVID-19 infection. Avacta… Read More

#Covid-19 #News

#Biologics / Biotechnology #Cell therapy #Clinical trials #Drug development #Drug discovery #Gene therapy #Imaging #Immunology / Virology & Vaccines #RNA

Cobra Biologics signs manufacture agreement with AstraZeneca for COVID-19 vaccine candidate

Cobra Biologics will provide GMP manufacture of the adenovirus vector-based COVID-19 vaccine candidate AZD1222, previously known as ChAdOx1 n-CoV-19. Cobra Biologics, part of the Cognate BioServices family, an international CDMO for biologics and pharmaceuticals, has signed a supply agreement with AstraZeneca UK to provide GMP manufacture of the adenovirus vector-based… Read More

#Covid-19 #News

#Analysis #Biologics / Biotechnology #Business #Clinical trials #Drug discovery #Imaging #Immunology / Virology & Vaccines

Novasep teams up with AstraZeneca to produce COVID-19 vaccine for Europe

Novasep, viral vector producer, has signed a partnership with AstraZeneca for the production of the Oxford University COVID-19 vaccine. Novasep will produce the active substance of the vaccine in its Belgian facilities The partnership follows the agreement between AstraZeneca and the Inclusive Alliance for Vaccines (IAV), to supply… Read More

#Covid-19 #News

#Biologics / Biotechnology #Clinical trials #Immunology #RNA

Janssen new data show improvements for active psoriatic arthritis

05 June, 2020 Janssen Pharmaceuticals has announced that new data from two phase 3 trials Discover-1 and Discover-2 showed that TREMFYA (guselkumab) maintained improvements in multiple clinical outcomes in adult patients with active psoriatic arthritis (PsA). The Janssen Pharmaceutical Companies of Johnson & Johnson said that new data… Read More

#News

#Biologics / Biotechnology

GSK and Samsung Biologics partner for additional manufacturing capacity

26 May, 2020 GlaxoSmithKline (GSK) and Samsung Biologics announced they have entered into a partnership to provide GSK with additional capacity to manufacture and supply its innovative biopharmaceutical therapies. Under the terms of the agreement, Samsung Biologics is to provide GSK with additional capacity for large-scale biopharmaceutical product… Read More

#News

#Biologics / Biotechnology #Business #Cell therapy #Gene therapy #Immunology #Oncology #Preclinical #Therapeutics

Boehringer Ingelheim acquires Northern Biologics’ Preclinical Cancer Antibody Pipeline

18 May, 2020 The research-driven pharmaceutical company said the new acquisition provides assets targeting the tumour stroma and myeloid cells. Boehringer Ingelheim also announced it is collaborating with CDR-Life to develop antibody fragment-based therapeutics for geographic atrophy, a leading cause of blindness. The first programme, now in late… Read More

#News

#Animal models #Biologics / Biotechnology #Clinical trials #Drug development #Drug discovery #Genetics / genomes #Immunology / Virology & Vaccines #Regulatory #RNA

Insect-based technology for human vaccines

06 May, 2020 Spain based private biotechnology company Algenex announced that it is advancing the application of its CrisBio-based vaccine production technology in human health. Building on its expertise in the production of proteins for veterinary vaccines, Algenex said it has started to produce biotechnology products for the… Read More

#News

#Biologics / Biotechnology #Clinical trials #Drug development #Drug discovery #High Content Screening #Imaging #Immunology / Virology & Vaccines #Precision medicine #RNA

Oxford University and AstraZeneca partner for COVID-19 vaccine candidate

Oxford University and its spin-out company Vaccitech announced an agreement with UK based biopharmaceutical specialist AstraZeneca for the further development, large-scale manufacture and potential distribution of the COVID-19 vaccine candidate, currently being trialled by the University. With immediate effect, the partnership is said to allow for rapid vaccination… Read More

#Covid-19 #News

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development optimisation & technology #Biologics / Biotechnology #Biomarkers #Business #Cell therapy #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #High Content Screening #Immunology #Immunology / Virology & Vaccines #Lead discovery #Mass spectrometry / NMR #Medicinal chemistry #Molecular medicine #Oncology #Pharmokinetics #Precision medicine #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Stem cells #System biology #Systems biology #Therapeutics

Meeting analytical challenges in a brave new world of next generation biotherapeutics

Meeting analytical challenges in a brave new world of next generation biotherapeutics By Mani Krishnan and Susan Darling Volume 21 Issue 2 - Spring 2020 The need for innovative advanced analytical tools to accelerate the development of immunotherapies and other complex biologics that may one day cure genetic diseases and… Read More

#Exclusive Content

#Animal models #Biologics / Biotechnology #Cell therapy #Cellular & Molecular biology #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug targets #Gene therapy #Genetics / genomes #High Content Screening #Immunology #Oncology #Orphan drugs #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Stem cells #Therapeutics #Toxicology

ADCs and solid tumours – The payload revolution that drives therapeutic opportunities in unmet need

ADCs and solid tumours - The payload revolution that drives therapeutic opportunities in unmet need By Dr Jenny Thirlway Volume 21 Issue 2 - Spring 2020 The fight against cancer is ongoing. Despite progress in many indications, mortality rates for some of the most difficult to treat solid tumour types… Read More

#Exclusive Content

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Biologics / Biotechnology #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene editing #Gene therapy #Genetics / genomes #In Silico Biology #Lead discovery #Molecular medicine #Oncology #Precision medicine #Protein chemistry / Proteomics #Regenerative Medicine #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Toxicology

Reprogramming the stem cell for a new generation of cures

Reprogramming the stem cell for a new generation of cures By Dr Alex Davenport, Dr Tonya Frolov and Dr Mark Kotter Volume 21 Issue 2 - Spring 2020 The development of new and effective treatments with the potential to cure, or at the very least ease patient suffering, has been… Read More

#Exclusive Content

#Academic #AI / data analytics / healthtech / informatics #Automation / robotics #Biologics / Biotechnology #Business #Cell therapy #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Lead discovery #Molecular medicine #Oncology #Orphan drugs #Preclinical #RNA #System biology #Systems biology #Therapeutics

Drug development 2.0 – The partnership model in practice

Drug development 2.0 - The partnership model in practice By Dr Brian Sheehan and Marco Cerato Over the last decade there has been a fundamental shift in the way in which drugs are developed and brought to market. Some years ago, the industry started to see profits falling as research… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Automation / robotics #Biologics / Biotechnology #Business #Cell therapy #Cellular & Molecular biology #Chemical engineering #Chemistry #Clinical specialities #Computational chemistry #Drug development #Drug discovery #Drug targets #Gene therapy #High Content Screening #Imaging #Immunology #Immunology / Virology & Vaccines #Lead discovery #Lead optimisation #Medicinal chemistry #Oncology #PCR #Preclinical #RNA #Therapeutics

Cryo-EM accelerates drug discovery by delivering previously intractable structural insights

Cryo-EM accelerates drug discovery by delivering previously intractable structural insights By Hans Raaijmakers, et al. Cryo-electron microscopy (cryo-EM), a powerful biophysical technique that can analyse molecular assemblies, is changing the paradigm in structure-based drug design. As targets become more challenging, solving structures of drug target molecules or biologics becomes increasingly… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Biologics / Biotechnology #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug repositioning #Drug targets #Enabling technologies #Gene editing #Gene therapy #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Immunology / Virology & Vaccines #In Silico Biology #Lead discovery #Microbiome #Molecular medicine #Nanomedicine / nanotechnology #Oncology #Patent Law #Precision medicine #Protein chemistry / Proteomics #Regenerative Medicine #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Therapeutics #Toxicology

2030 Life Sciences and Health in the Digital Age (Part 2)

By Dr Steve Arlington and John Wise As part of its mission to help members anticipate and prepare for changes in the pharmaceutical industry, The Pistoia Alliance has developed a research paper which sets out to consider what the life science, biopharma R&D and healthcare ecosystem might look like in… Read More

#Exclusive Content

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biologics / Biotechnology #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Drug development #Drug discovery #Drug targets #Gene editing #Gene therapy #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Immunology #In Silico Biology #Lead discovery #Lead optimisation #Molecular medicine #Oncology #Orphan drugs #Pathology #Pharmacology #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation

Fail Early, Fail Fast – A phenotypic rescue approach

Fail Early, Fail Fast - A phenotypic rescue approach By Dr Anne-Marie Zuurmond, et al. New disease targets frequently emerge in literature, but the thorough target validation required to consider these targets for a drug discovery programme is often lacking. In pharmacological or genetic perturbation studies using complex biological assays,… Read More

#Archive